LOS ANGELES,Nov. 21,2024-- This holiday season,Yitahome invites you to redefine your space and make every moment count with #TheExtraordinaryWeeks campaign. From Thanksgiving to Christmas,enjoy aline-
BuzzCast Short Video Contest Concludes Successfully, Honoring the Five Grand Winners
The factory building project of the second phase of Fujian Three Gorges Offshore Wind Power Industrial Park passed completion acceptance
RiDYMO® Platform Drives New Breakthroughs in highly potent PLK1 Inhibitors Development
BEIJING,Nov. 19,2024-- With the support of the RiDYMO® platform,we are able to comprehensively explore various potential targets in drug development,including protein-protein interactions,kinases,
The investment will initially focus on expediting development at existing sites inNavi Mumbai and Ambattur,Chennai,with an additional third site to be added in future.
Pop Culture Announces Improvement in Overall Operations During the Fiscal Year Ended June 30, 2024
XIAMEN,China,Nov. 19,2024-- In the fiscal year ended June 30,2024,POP CULTURE GROUP CO.,LTD. ("Pop Culture," or the "Company," Nasdaq: CPOP) continued to focus on its three busines
48-week end-of-treatment data from theongoing Phase 2 ENSURE study clearly demonstrated the added benefits of elebsiran towards achieving a higher functional cure rate in combination with PEG-IFNα
Neo4j Surpasses $200M in Revenue, Accelerates Leadership in GenAI-Driven Graph Technology
Database pioneer continues to scale at $2B+ valuation as GenAI accelerates demand SAN MATEO,Calif.,Nov. 19,2024--Neo4j®,the world\'s leading graph database and analytics company,announced that it
Ractigen Therapeutics Announces FDA Orphan Drug Designation for RAG-21 for the Treatment of ALS
NANTONG and SUZHOU,China,Nov. 19,2024-- Ractigen Therapeutics,a clinical-stage pharmaceutical company dedicated to developing innovative therapies,today announced that the U.S. Food and Drug Administr